The Evaluation of Injection Site Pain and Adherence in Patients Switching from a Low to High Concentration Adalimumab (AVT-02) Across Multiple Indications.
Active, not recruiting
- Conditions
- Crohn DiseaseAnkylosing SpondylitisPlaque PsoriasisHidradenitis SuppurativaUlcerative ColitisPsoriatic ArthritisRheumatoid Arthritis
- Interventions
- Biological: AVT02 (Alvotech Biosimilar to Adalimumab)
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Jamp Pharma Corporation
- Target Recruit Count
- 600
- Registration Number
- NCT05913817
- Locations
- 🇨🇦
JAMP Pharma Corporation, Montréal, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath